|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lynch TJ, Bell DW, Sordella R,
Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat
SM, Supko JG, Haluska FG, et al: Activating mutations in the
epidermal growth factor receptor underlying responsiveness of
non-small-cell lung cancer to gefitinib. N Engl J Med.
350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rosell R, Moran T, Queralt C, Porta R,
Cardenal F, Camps C, Majem M, Lopez-Vivanco G, Isla D, Provencio M,
et al: Screening for epidermal growth factor receptor mutations in
lung cancer. N Engl J Med. 361:958–967. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mok TS, Wu YL, Thongprasert S, Yang CH,
Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, et
al: Gefitinib or carboplatin-paclitaxel in pulmonary
adenocarcinoma. N Engl J Med. 361:947–957. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jackman D, Pao W, Riely GJ, Engelman JA,
Kris MG, Jänne PA, Lynch T, Johnson BE and Miller VA: Clinical
definition of acquired resistance to epidermal growth factor
receptor tyrosine kinase inhibitors in non-small-cell lung cancer.
J Clin Oncol. 28:357–360. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sequist LV, Waltman BA, Dias-Santagata D,
Digumarthy S, Turke AB, Fidias P, Bergethon K, Shaw AT, Gettinger
S, Cosper AK, et al: Genotypic and histological evolution of lung
cancers acquiring resistance to EGFR inhibitors. Sci Transl Med.
3:75ra262011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yu HA, Arcila ME, Rekhtman N, Sima CS,
Zakowski MF, Pao W, Kris MG, Miller VA, Ladanyi M and Riely GJ:
Analysis of tumor specimens at the time of acquired resistance to
EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.
Clin Cancer Res. 19:2240–2247. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ghosh G, Lian X, Kron SJ and Palecek SP:
Properties of resistant cells generated from lung cancer cell lines
treated with EGFR inhibitors. BMC Cancer. 12:952012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shien K, Toyooka S, Yamamoto H, Soh J,
Jida M, Thu KL, Hashida S, Maki Y, Ichihara E, Asano H, et al:
Acquired resistance to EGFR inhibitors is associated with a
manifestation of stem cell-like properties in cancer cells. Cancer
Res. 73:3051–3061. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Clarke MF, Dick JE, Dirks PB, Eaves CJ,
Jamieson CH, Jones DL, Visvader J, Weissman IL and Wahl GM: Cancer
stem cells-perspectives on current status and future directions:
AACR Workshop on cancer stem cells. Cancer Res. 66:9339–9344. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kocher O, Cheresh P and Lee SW:
Identification and partial characterization of a novel
membrane-associated protein (MAP17) up-regulated in human
carcinomas and modulating cell replication and tumor growth. Am J
Pathol. 149:493–500. 1996.PubMed/NCBI
|
|
12
|
Guijarro MV, Vergel M, Marin JJ,
Muñoz-Galván S, Ferrer I, Ramon y Cajal S, Roncador G,
Blanco-Aparicio C and Carnero A: p38α limits the contribution of
MAP17 to cancer progression in breast tumors. Oncogene.
31:4447–4459. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Di Maro G, Orlandella FM, Bencivenga TC,
Salerno P, Ugolini C, Basolo F, Maestro R and Salvatore G:
Identification of targets of Twist1 transcription factor in thyroid
cancer cells. J Clin Endocrinol Metab. 99:E1617–1626. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Inoue J, Otsuki T, Hirasawa A, Imoto I,
Matsuo Y, Shimizu S, Taniwaki M and Inazawa J: Overexpression of
PDZK1 within the 1q12-q22 amplicon is likely to be associated with
drug-resistance phenotype in multiple myeloma. Am J Pathol.
165:71–81. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Dontu G, Abdallah WM, Foley JM, Jackson
KW, Clarke MF, Kawamura MJ and Wicha MS: In vitro propagation and
transcriptional profiling of human mammary stem/progenitor cells.
Genes Dev. 17:1253–1270. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Singh SK, Clarke ID, Terasaki M, Bonn VE,
Hawkins C, Squire J and Dirks PB: Identification of a cancer stem
cell in human brain tumors. Cancer Res. 63:5821–5828.
2003.PubMed/NCBI
|
|
18
|
Al-Hajj M: Cancer stem cells and oncology
therapeutics. Curr Opin Oncol. 19:61–64. 2007.PubMed/NCBI
|
|
19
|
Liu S, Dontu G and Wicha MS: Mammary stem
cells, self-renewal pathways, and carcinogenesis. Breast Cancer
Res. 7:86–95. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Boiani M and Schöler HR: Regulatory
networks in embryo-derived pluripotent stem cells. Nat Rev Mol Cell
Biol. 6:872–884. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Dean M, Fojo T and Bates S: Tumour stem
cells and drug resistance. Nat Rev Cancer. 5:275–284. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Carnero A: MAP17 and the double-edged
sword of ROS. Biochim Biophys Acta. 1826:44–52. 2012.PubMed/NCBI
|
|
23
|
Perez M, Praena-Fernandez JM, Felipe-Abrio
B, Lopez-Garcia MA, Lucena-Cacace A, Garcia A, Lleonart M, Roncador
G, Marin JJ and Carnero A: MAP17 and SGLT1 protein expression
levels as prognostic markers for cervical tumor patient survival.
PLoS One. 8:e561692013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Guijarro MV, Leal JF, Blanco-Aparicio C,
Alonso S, Fominaya J, Lleonart M, Castellvi J, Ramon Y Cajal S and
Carnero A: MAP17 enhances the malignant behavior of tumor cells
through ROS increase. Carcinogenesis. 28:2096–2104. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ponti D, Costa A, Zaffaroni N, Pratesi G,
Petrangolini G, Coradini D, Pilotti S, Pierotti MA and Daidone MG:
Isolation and in vitro propagation of tumorigenic breast cancer
cells with stem/progenitor cell properties. Cancer Res.
65:5506–5511. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Patrawala L, Calhoun T,
Schneider-Broussard R, Zhou J, Claypool K and Tang DG: Side
population is enriched in tumorigenic, stem-like cancer cells,
whereas ABCG2+ and ABCG2-cancer cells are similarly tumorigenic.
Cancer Res. 65:6207–6219. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Leung EL, Fiscus RR, Tung JW, Tin VP,
Cheng LC, Sihoe AD, Fink LM, Ma Y and Wong MP: Non-small cell lung
cancer cells expressing CD44 are enriched for stem cell-like
properties. PLoS One. 5:e140622010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Takanami I, Takeuchi K and Naruke M:
Expression and prognostic value of the standard CD44 protein in
pulmonary adenocarcinoma. Oncol Rep. 7:1065–1067. 2000.PubMed/NCBI
|
|
29
|
Kobayashi I, Takahashi F, Nurwidya F, Nara
T, Hashimoto M, Murakami A, Yagishita S, Tajima K, Hidayat M,
Shimada N, et al: Oct4 plays a crucial role in the maintenance of
gefitinib-resistant lung cancer stem cells. Biochem Biophys Res
Commun. 473:125–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hashida S, Yamamoto H, Shien K, Miyoshi Y,
Ohtsuka T, Suzawa K, Watanabe M, Maki Y, Soh J, Asano H, et al:
Acquisition of cancer stem cell-like properties in non-small cell
lung cancer with acquired resistance to afatinib. Cancer Sci.
106:1377–1384. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ho R, Minturn JE, Hishiki T, Zhao H, Wang
Q, Cnaan A, Maris J, Evans AE and Brodeur GM: Proliferation of
human neuroblastomas mediated by the epidermal growth factor
receptor. Cancer Res. 65:9868–9875. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Huang G, Yan H, Ye S, Tong C and Ying QL:
STAT3 phosphorylation at tyrosine 705 and serine 727 differentially
regulates mouse ESC fates. Stem Cells. 32:1149–1160. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wang D, Lu P, Zhang H, Luo M, Zhang X, Wei
X, Gao J, Zhao Z and Liu C: Oct-4 and Nanog promote the
epithelial-mesenchymal transition of breast cancer stem cells and
are associated with poor prognosis in breast cancer patients.
Oncotarget. 5:10803–10815. 2014.PubMed/NCBI
|
|
34
|
Lage H: An overview of cancer multidrug
resistance: A still unsolved problem. Cell Mol Life Sci.
65:3145–3167. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lanaspa MA, Giral H, Breusegem SY,
Halaihel N, Baile G, Catalán J, Carrodeguas JA, Barry NP, Levi M
and Sorribas V: Interaction of MAP17 with NHERF3/4 induces
translocation of the renal Na/Pi IIa transporter to the
trans-Golgi. Am J Physiol Renal Physiol. 292:F230–F242. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
de Miguel-Luken MJ, Chaves-Conde M,
Quintana B, Menoyo A, Tirado I, de Miguel-Luken V, Pachón J,
Chinchón D, Suarez V and Carnero A: Phosphorylation of gH2AX as a
novel prognostic biomarker for laryngoesophageal dysfunction-free
survival. Oncotarget. 7:31723–31737. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wang N, Zhou F, Xiong H, Du S, Ma J, Okai
I, Wang J, Suo J, Hao L, Song Y, et al: Screening and
identification of distant metastasis-related differentially
expressed genes in human squamous cell lung carcinoma. Anat Rec
(Hoboken). 295:748–757. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
de Miguel-Luken MJ, Chaves-Conde M, de
Miguel-Luken V, Muñoz-Galván S, López-Guerra JL, Mateos JC, Pachón
J, Chinchón D, Suarez V and Carnero A: MAP17 (PDZKIP1) as a novel
prognostic biomarker for laryngeal cancer. Oncotarget.
6:12625–12636. 2015. View Article : Google Scholar : PubMed/NCBI
|
